Skip to main content
Top
Published in: Breast Cancer 4/2020

01-07-2020 | Breast Cancer | Original Article

miR-485-5p inhibits the progression of breast cancer cells by negatively regulating MUC1

Authors: Xiaowen Wang, Xin Zhou, Fanye Zeng, Xiaotang Wu, Hua Li

Published in: Breast Cancer | Issue 4/2020

Login to get access

Abstract

Objective

To investigate the mechanism of miR-485-5p inhibiting breast cancer cells by targeting MUC1.

Methods

Differentially expressed genes (DEGs) in breast cancer tissues were analyzed using breast cancer tissue microarrays (TMA) in the GEO database. Differential expression of MUC1 in breast cancer tissue samples was detected by TCGA database. qRT-PCR was used to detect the expression of MUC1 and miR-485-5p in human normal breast epithelial cell lines and human breast cancer cell lines. Bioinformatics was applied to analyze targeted binding site of miR-485-5p and MUC1 and their targeted relationship was identified by dual luciferase assay. The proliferation ability of breast cancer cells was detected by CCK-8 assay. Cell apoptosis was detected by flow cytometry. The ability of cell migration was measured by scratch healing test. Transwell assay was used to detect the invasion ability of cells. The protein expression levels of MUC1 and EMT-related molecules (E-cadherin, N-cadherin and Vimentin) were detected by Western blot.

Results

MUC1 was highly expressed in breast cancer tissue samples and breast cancer cell lines, while miR-485-5p was lowly expressed. Overexpression of miR-485-5p inhibits cell viability and invasion and migration of breast cancer cell line MCF-7 and promotes apoptosis. The same results were obtained by silencing the expression of MUC1. MiR-485-5p targets to bind to the 3′-UTR region of MUC1 and negatively regulates the expression of MUC1. Overexpressing MUC1 while overexpressing miR-485-5p reversed the inhibitory effect of miR-485-5p on breast cancer and inhibited EMT.

Conclusion

MiR-485-5p can down-regulate the expression of MUC1, thus inhibit the proliferation, invasion and migration of breast cancer cells and promote cell apoptosis.
Literature
1.
go back to reference DeSantis CE, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–48.CrossRef DeSantis CE, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–48.CrossRef
2.
go back to reference Rheinbay E, et al. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017;547(7661):55–60.CrossRef Rheinbay E, et al. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017;547(7661):55–60.CrossRef
3.
go back to reference Peng Y, Croce CM. The role of microRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.CrossRef Peng Y, Croce CM. The role of microRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.CrossRef
4.
go back to reference Hata A, Kashima R. Dysregulation of microRNA biogenesis machinery in cancer. Crit Rev Biochem Mol Biol. 2016;51(3):121–34.CrossRef Hata A, Kashima R. Dysregulation of microRNA biogenesis machinery in cancer. Crit Rev Biochem Mol Biol. 2016;51(3):121–34.CrossRef
5.
go back to reference Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2005;353(17):1768–71.CrossRef Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2005;353(17):1768–71.CrossRef
6.
go back to reference Lin XJ, et al. hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. Int J Mol Med. 2017;40(1):83–9.CrossRef Lin XJ, et al. hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. Int J Mol Med. 2017;40(1):83–9.CrossRef
7.
go back to reference Duan J, et al. The role of miR-485-5p/NUDT1 axis in gastric cancer. Cancer Cell Int. 2017;17:92.CrossRef Duan J, et al. The role of miR-485-5p/NUDT1 axis in gastric cancer. Cancer Cell Int. 2017;17:92.CrossRef
8.
go back to reference Jing LL, Mo XM. Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer. Eur Rev Med Pharmacol Sci. 2016;20(8):1516–20.PubMed Jing LL, Mo XM. Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer. Eur Rev Med Pharmacol Sci. 2016;20(8):1516–20.PubMed
9.
go back to reference Kang M, et al. miR-485-5p acts as a negative regulator in gastric cancer progression by targeting flotillin-1. Am J Transl Res. 2015;7(11):2212–22.PubMedPubMedCentral Kang M, et al. miR-485-5p acts as a negative regulator in gastric cancer progression by targeting flotillin-1. Am J Transl Res. 2015;7(11):2212–22.PubMedPubMedCentral
10.
go back to reference Lou C, et al. MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1alpha expression. Cell Death Dis. 2016;7:e2159.CrossRef Lou C, et al. MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1alpha expression. Cell Death Dis. 2016;7:e2159.CrossRef
11.
go back to reference Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874–85.CrossRef Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874–85.CrossRef
12.
go back to reference Sinn BV, et al. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2013;24(9):2316–24.CrossRef Sinn BV, et al. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2013;24(9):2316–24.CrossRef
13.
go back to reference Haddon L, Hugh J. MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad. Clin Exp Metastasis. 2015;32(4):393–403.CrossRef Haddon L, Hugh J. MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad. Clin Exp Metastasis. 2015;32(4):393–403.CrossRef
14.
go back to reference Carmon L, et al. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015;169(1):44–56.CrossRef Carmon L, et al. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015;169(1):44–56.CrossRef
15.
go back to reference Kovjazin R, et al. Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy. PLoS ONE. 2014;9(1):e85400.CrossRef Kovjazin R, et al. Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy. PLoS ONE. 2014;9(1):e85400.CrossRef
16.
go back to reference Goode G, et al. Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer. PLoS ONE. 2017;12(6):e0179098.CrossRef Goode G, et al. Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer. PLoS ONE. 2017;12(6):e0179098.CrossRef
17.
go back to reference Mohit E, Hashemi A, Allahyari M. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert Rev Clin Immunol. 2014;10(7):927–61.CrossRef Mohit E, Hashemi A, Allahyari M. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert Rev Clin Immunol. 2014;10(7):927–61.CrossRef
18.
go back to reference Jing X, et al. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep. 2019;41(2):801–10.PubMed Jing X, et al. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep. 2019;41(2):801–10.PubMed
19.
go back to reference von Mensdorff-Pouilly S, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol. 2000;18(3):574–83.CrossRef von Mensdorff-Pouilly S, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol. 2000;18(3):574–83.CrossRef
20.
go back to reference Bell R, Barraclough R, Vasieva O. Gene expression meta-analysis of potential metastatic breast cancer markers. Curr Mol Med. 2017;17(3):200–10.CrossRef Bell R, Barraclough R, Vasieva O. Gene expression meta-analysis of potential metastatic breast cancer markers. Curr Mol Med. 2017;17(3):200–10.CrossRef
21.
go back to reference Lu H, et al. Human mitotic centromere-associated KINESIN IS TARGETED BY MicroRNA 485-5p/181c and prognosticates poor survivability of breast cancer. J Oncol. 2019;2019:2316237.PubMedPubMedCentral Lu H, et al. Human mitotic centromere-associated KINESIN IS TARGETED BY MicroRNA 485-5p/181c and prognosticates poor survivability of breast cancer. J Oncol. 2019;2019:2316237.PubMedPubMedCentral
22.
go back to reference Costa FF, et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS ONE. 2011;6(10):e25114.CrossRef Costa FF, et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS ONE. 2011;6(10):e25114.CrossRef
23.
go back to reference Kim TH, et al. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology. 2010;57(5):734–43.CrossRef Kim TH, et al. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology. 2010;57(5):734–43.CrossRef
24.
go back to reference Merikhian P, et al. MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer. Expert Rev Anticancer Ther. 2017;17(7):607–13.CrossRef Merikhian P, et al. MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer. Expert Rev Anticancer Ther. 2017;17(7):607–13.CrossRef
25.
go back to reference McGuckin MA, et al. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol. 1995;26(4):432–9.CrossRef McGuckin MA, et al. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol. 1995;26(4):432–9.CrossRef
26.
go back to reference Yuan H, et al. Mucin 1 gene silencing inhibits the growth of SMMC-7721 human hepatoma cells through Bax-mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways. Mol Med Rep. 2015;12(5):6782–8.CrossRef Yuan H, et al. Mucin 1 gene silencing inhibits the growth of SMMC-7721 human hepatoma cells through Bax-mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways. Mol Med Rep. 2015;12(5):6782–8.CrossRef
27.
go back to reference Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle. 2010;9(12):2363–74.CrossRef Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle. 2010;9(12):2363–74.CrossRef
Metadata
Title
miR-485-5p inhibits the progression of breast cancer cells by negatively regulating MUC1
Authors
Xiaowen Wang
Xin Zhou
Fanye Zeng
Xiaotang Wu
Hua Li
Publication date
01-07-2020
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2020
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-020-01075-2

Other articles of this Issue 4/2020

Breast Cancer 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine